PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first-quarter ended March 31, 2017.
“During the first quarter of 2017, The Medicine Company continued to deliver excellent execution against our 2017 objectives, significantly advancing key development programs, strictly managing cash deployment to enhance our ability to support our products and pipeline going forward, maintaining maximum strategic and operational flexibility and positioning us to drive shareholder value,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “Nowhere is that execution excellence more evident than in our press release this morning announcing our agreement with the FDA on the Phase III development program for inclisiran. We believe this agreement adds significantly to the strategic value of inclisiran, and follows the presentation of positive final results from the ORION-1 Phase II study of inclisiran at the American College of Cardiology’s 66th Annual Scientific Session on March 17, 2017. Those results, which were simultaneously published in The New England Journal of Medicine, demonstrated inclisiran’s unique and highly-differentiated attributes and its game-changing potential.”
